

Biotech M&A and Partnerships: Innovation and Deal-Making in Challenging Markets



As part of Goodwin's exclusive programming during the BIO International Convention in Boston, we invite you to join us for a session spotlighting the evolving world of M&A and strategic partnerships in a rapidly shifting biotech landscape.

Through a dynamic fireside chat and expert panel discussions, we'll uncover innovative deal-making strategies, explore how biopharma companies are forging smart alliances, and reveal the pivotal decisions driving growth in unpredictable times.

Don't miss this opportunity to gain actionable insights, hear from industry insiders, and connect with the leaders shaping the future of biotech. This event is in partnership with PJT Partners.

Please RSVP [here](#) and see below for more details!

Date & Time: Wednesday, June 18 from 12:00 PM - 2:30 PM ET

Location: Goodwin's Boston Office, 100 Northern Avenue, Boston, MA 02210

12:00 - 12:30 PM | Registration and Lunch

12:30 PM - 12:40 PM | Opening Remarks

12:40 PM - 1:15 PM | Fireside Chat: Biopharma Strategy in Volatile Times

- Rob Masella, Partner, Goodwin
- Daniel Lee, Partner, Healthcare Group, PJT Partners

1:15 PM - 2:00 PM | Panel Discussion: Current Perspectives on M&A and Partnering: Finding Strategic Alignment

- Erini Svokos, Partner, Goodwin (Moderator)
- Rajeev Dadoo, PhD, COO & Managing Partner, SR One
- Daniel Rosan, Chief Financial and Business Officer, Ascidian Therapeutics

2:00 PM - 2:10 PM | Audience Q&A & Closing Remarks

Medtech M&A and VC Signal Positive Momentum Entering 2025



Medtech mergers and acquisitions (M&A) and venture capital (VC) showed signs of life in 2024, contributing to an overall optimistic outlook for the sector this year despite lingering headwinds.

Strategic investments are expected to continue as medtech companies innovate, particularly in areas such as AI-driven diagnostics, wearables and remote monitoring devices, and advanced surgical technologies.

Private, venture-backed M&A activity for medical devices—which picked up in the second half of last year and started 2025 strong with two ten-digit acquisitions and two spin-offs by strategics—could continue rising amid a more deregulatory backdrop under the new presidential administration.

Still, challenges persist that could slow growth. Early-stage VC deals in the sector have faced difficulties, and private M&A exit timelines have increased. Uncertainty regarding the path of interest rates and the broader economy also muddy the outlook.

Read the full insight [here](#).

European Life Sciences Deal Trends



In Europe, life sciences deals increased over the last few years with a strong acceleration in 2021. As a result, the market wonders whether this is just a pick or rather a steady trend which will impact our market in the future as well. Analyzing the reasons of such growth and comparing it with more

mature markets such as the U.S. comfort us in thinking that it is just the beginning for continental Europe.

The U.S. life sciences market has been very strong over the past decades and is seen as very mature. The level of venture investments, which are now very much standardized, licensing, M&A and IPOs is very high, both in volume and in number.

For the last ten years or so, the life sciences UK market attracted U.S. investors and an increasing number of growth funds. After a first step of development through venture investments, such companies are now ready for licensing, M&A and IPOs. This is also the trend that we anticipate for the European market even if each country or region still has its own specificities (in particular UK, Germany, France and the Nordic Countries).

Read the [client alert](#).

Survival Guide to Structuring Life Sciences Partnering and M+A Agreements



The life sciences space is ever-growing and dynamic as the industry witnesses more companies and, therefore, more collaboration, licensing and M&A agreements, come into the spotlight. While these deals are exciting opportunities for life sciences companies at all stages, they can also be daunting when it comes to their legal structure.

In order to best leverage assets, align incentives, allocate risk and draft agreements to position your partnership for success, Goodwin recommends considering the following business, legal and litigation perspectives as you navigate these type of agreements.

Read the [full insight](#).

COVID-19 and the Impact on M&A



Although COVID-19 is rightfully viewed primarily as a public health and humanitarian issue, it is worth considering the potential impacts of the virus on M&A activity as this dynamic situation unfolds. We are seeing the issue find its way into M&A processes in various ways, and we have highlighted many of the issues here.

[Read the Alert >>](#)